Roche had filed for patent of 'Herceptin' on October 11, 2000 and was granted a patent on April 6, 2007 but faced a post grant challenge.
Following it, according to the Ministry of Commerce and Industry, the Controllers of the Patent Office gave the company opportunity under three applications filed by it "of being heard before the final disposition of these cases".
Also Read
"Before the Controllers issued their decisions, the applicants were given due opportunity of being heard but the applicants have chosen not to attend."
"It is submitted that in the instant cases, the Patent Office has followed the due course of principle of natural justice, gave the applicant the opportunity of being heard and then only finally disposed of the matter," the ministry said in a statement.
In the instant cases, it is found that proper steps for filing request or filing divisional applications were not followed by the applicants, it added.
Comments from Roche could not be obtained as an emailed query remained unanswered.
Putting the blame squarely on the pharmaceutical major, the ministry said: "If the requests are not filed within time they are treated as withdrawn under section IIB(4) of the (Indian Patents) Act".
Elaborating how the company had failed to adhere to deadlines, the ministry said "the patent controller found that the Request for Examination had been filed on 17.03.2006, i.e., beyond the prescribed period (which was due on 16.02.2006)" as per the Indian patent norms.
It further said two separate dates were given to the company this year by the controller to hear its case but "the agent of the applicant did not appear in the hearing and even did not submit any notes of argument. Under these circumstances, the controller ordered that the application should be treated as withdrawn."
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app